KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders

US8029986B2 · kind B2 · utility

Assignees

• Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE
• Eberhard Karls Universität Tübingen · DE
• Mayo Foundation for Medical Education and Research · US

Inventors

• Thomas Meitinger · Munich, DE
• Tim Matthias Strom · Munich, DE
• Saskia Biskup · Stuttgart, DE
• Marius Ueffing · Munich, DE
• Elisabeth Kremmer · Freising, DE
• Christian Gloeckner · Bonn, DE
• Thomas Gasser · Lörrach, DE
• Petra Herzig · Basel, CH
• Friedrich Asmus · Sömmerda, DE
• Nadja Patenge · Rostock, DE
• Alexander Zimprich · Clare, AU
• Matthew J. Farrer · Jacksonville, US
• Jennifer M. Kachergus · Atlantic Beach, US
• Sara J. Lincoln · Jacksonville, US
• Mary M. Hulihan · Atlanta, US
• Zibigniew Wszolek · Jacksonville, US
• Ryan Uitti · Jacksonville, US

Key dates

• Filing date: Sep 27, 2005
• Grant date: Oct 4, 2011
• Expiry date: Feb 9, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.